Evonik Industries AG

Steag, through its subsidiaries, is engaged mainly in power generation and related industries. Co.'s business is divided into five units: Power generation, Decentralized Energy Supply, Foreign Power Plants, Gas Distribution, and Coal Trading.
  • TickerEVNK01
  • ISINDE000EVNK013
  • SectorChemicals
  • CountryGermany

Analysts

1 director bought

A director at Evonik Industries AG bought 2,000 shares at 24.682EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names o...

Rob Hales

Morningstar | Evonik Gets Good Price on Methacrylates Sale; Dividend Shored Up

No-moat Evonik shares traded up 5% intraday after the company announced a better-than-expected sale price for its methacrylates business and a sustainable annual cash flow increase of EUR 100 million from pension reimbursements. The pension reimbursement was a surprise and provides much-needed security for dividend coverage with loss of the methacrylates cash flow contribution. Fourth-quarter results were in line with expectations, but guidance for 2019 is slightly lower than our forecast. We are likely to trim our near-term forecast, but this is offset by the methacrylates sale. Consequently,...

Rob Hales

Evonik Gets Good Price on Methacrylates Sale; Dividend Shored Up

No-moat Evonik shares traded up 5% intraday after the company announced a better-than-expected sale price for its methacrylates business and a sustainable annual cash flow increase of EUR 100 million from pension reimbursements. The pension reimbursement was a surprise and provides much-needed security for dividend coverage with loss of the methacrylates cash flow contribution. Fourth-quarter results were in line with expectations, but guidance for 2019 is slightly lower than our forecast. We ar...

Evonik Industries AG - December 2017 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Evonik Industries AG - September 2017 (LTM): Peer Snapshot

Peer Snapshot:  Evonik Industries AG - September 2017 (LTM) 4 January 2018 (in US millions) FYE Dec-15 FYE Dec-16 LTM Sep-17 FYE Dec-15 FYE Dec-16 LTM Sep-17 FYE Dec-15 FYE Dec-16 LTM

Evonik Industries AG - June 2017 (LTM): Peer Snapshot

Peer Snapshot:  Evonik Industries AG - June 2017 (LTM) 4 October 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Jun-17 FYE Dec-15 FYE Dec-16 LTM Jun-17 FYE Dec-15 FYE Dec-16 LTM Jun-17

Moody's assigns (P)Baa3 rating to Evonik's new hybrid notes; stable outlook

Rating Action: Moody's assigns Baa3 rating to Evonik's new hybrid notes; stable outlook. Global Credit Research- 28 Jun 2017. London, 28 June 2017-- Moody's Investors Service, has today assigned a provisional Baa3 rating to the proposed issuance of Subordinated Resettable Fixed Rate Notes by Evonik Industries AG.

Evonik Industries AG - March 2017 (LTM): Peer Snapshot

Peer Snapshot:  Evonik Industries AG - March 2017 (LTM) 7 June 2017 (in US millions) FYE Dec-15 FYE Dec-16 LTM Mar-17 FYE Dec-14 FYE Dec-15 LTM Dec-16 FYE Dec-14 FYE Dec-15 LTM Dec-16

Rob Hales

Morningstar | Evonik Gets Good Price on Methacrylates Sale; Dividend Shored Up

No-moat Evonik shares traded up 5% intraday after the company announced a better-than-expected sale price for its methacrylates business and a sustainable annual cash flow increase of EUR 100 million from pension reimbursements. The pension reimbursement was a surprise and provides much-needed security for dividend coverage with loss of the methacrylates cash flow contribution. Fourth-quarter results were in line with expectations, but guidance for 2019 is slightly lower than our forecast. We are likely to trim our near-term forecast, but this is offset by the methacrylates sale. Consequently,...

Rob Hales

Evonik Gets Good Price on Methacrylates Sale; Dividend Shored Up

No-moat Evonik shares traded up 5% intraday after the company announced a better-than-expected sale price for its methacrylates business and a sustainable annual cash flow increase of EUR 100 million from pension reimbursements. The pension reimbursement was a surprise and provides much-needed security for dividend coverage with loss of the methacrylates cash flow contribution. Fourth-quarter results were in line with expectations, but guidance for 2019 is slightly lower than our forecast. We ar...

Rob Hales

Morningstar | Evonik Continues to Actively Reshape Its Portfolio

Evonik was publicly listed in 2013 by its majority owner, RAG-Stiftung, which still holds 67.9% of the shares. The company debuted as a conglomerate with energy and real estate divisions in addition to chemicals; however, those noncore businesses were quickly divested. Evonik's long-term goals include volume growth above GDP and an 18%-20% EBITDA margin through focusing on four growth engines: health and care, smart materials, specialty additives, and animal nutrition. In the company's current form, we think the EBITDA margin target will be tough to achieve. Consequently, Evonik continues to b...

Dr. Knud Hinkel, CFA

EVONIK - Acquiring PeroxyChem - no nonsense

Rob Hales

Morningstar | Evonik's Soft PMMA/MMA Outlook Overshadows Solid 3Q Results; Shares Undervalued

No-moat Evonik reported third-quarter EBITDA of EUR 692 million, up 8% over 2017 and in line with consensus and our expectations. It confirmed 2018 guidance. Despite solid results, the stock is trading down 4% at time of writing, the weakest in the group. We think the negative reaction in the share price probably reflects the first signs of normalization in the polymethyl methacrylate/methyl methacrylate markets, which have been overearning for an extended time. Evonik reported that supply was more balanced in PMMA/MMA with a less overheated market outlook. PMMA competitor Arkema reported a si...

1 director bought

A director at Evonik Industries AG bought 2,000 shares at 24.682EUR and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names o...

EVONIK INDUSTRIES AG sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of EVONIK INDUSTRIES AG (DE), a company active in the Specialty Chemicals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date January 18, 2019, the closing price was EUR 23.83 and its potential was estimated at EUR 25.89.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Evonik Industries – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch